Back to School: How biopharma can reboot drug development. Access exclusive analysis here
BRA reported data from a 17-patient Phase I trial showing that BLP25 was well tolerated
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury